Table 1

Analysis of TP53 mutations in FL and correlation with tumor stage and clinical outcome

Patient no.Age at diagnosis, yGenomic no.*Predicted amino acid no.†LocationPredicted effect‡Predicted TP53 function‡Disease stage at presentationInitial treatmentPFS, moOS, y
1 45 g.13216 T>A p.H179Q Exon 5 Missense Nonfunctional IIe Single-agent chemotherapy 10 7.7 
2 Not known g.14028 A>G p.Y234C Exon 7 Missense Nonfunctional Not known Multiagent chemotherapy 53 4.5 
3 47 g.14057 G>A p.G244S Exon 7 Missense Nonfunctional III Multiagent chemotherapy radiotherapy 11 5.0 
4 71 g.14060 G>A p.G245S Exon 7 Missense Nonfunctional II Radiotherapy 21 11.9 
5 64 g.14060 G>T p.G245C Exon 7 Missense Nonfunctional IV Expectant management 24 9.8 
6 59 g.14061 G>T p.G245V Exon 7 Missense Nonfunctional IV Multiagent chemotherapy 4 0.5 
7 65 g.14111 T>G NA Intron 7 Splice site Splice III Multiagent chemotherapy 11 0.9 
8 78 g.14486 C>T p.R273C Exon 8 Missense Nonfunctional III Multiagent chemotherapy 12 7.7 
9 53 g.14487 G>A p.R273H Exon 8 Missense Nonfunctional III Radiotherapy 25 4.4 
10 63 g.14487 G>A p.R273H Exon 8 Missense Nonfunctional II Multiagent chemotherapy 16 2.3 
11 63 g.14513 C>T p.R282W Exon 8 Missense Nonfunctional IV Multiagent chemotherapy 15 2.0 
12 75 g.14517 G>A p.R283H Exon 8 Missense Functional IV Multiagent chemotherapy 15 1.3 
Patient no.Age at diagnosis, yGenomic no.*Predicted amino acid no.†LocationPredicted effect‡Predicted TP53 function‡Disease stage at presentationInitial treatmentPFS, moOS, y
1 45 g.13216 T>A p.H179Q Exon 5 Missense Nonfunctional IIe Single-agent chemotherapy 10 7.7 
2 Not known g.14028 A>G p.Y234C Exon 7 Missense Nonfunctional Not known Multiagent chemotherapy 53 4.5 
3 47 g.14057 G>A p.G244S Exon 7 Missense Nonfunctional III Multiagent chemotherapy radiotherapy 11 5.0 
4 71 g.14060 G>A p.G245S Exon 7 Missense Nonfunctional II Radiotherapy 21 11.9 
5 64 g.14060 G>T p.G245C Exon 7 Missense Nonfunctional IV Expectant management 24 9.8 
6 59 g.14061 G>T p.G245V Exon 7 Missense Nonfunctional IV Multiagent chemotherapy 4 0.5 
7 65 g.14111 T>G NA Intron 7 Splice site Splice III Multiagent chemotherapy 11 0.9 
8 78 g.14486 C>T p.R273C Exon 8 Missense Nonfunctional III Multiagent chemotherapy 12 7.7 
9 53 g.14487 G>A p.R273H Exon 8 Missense Nonfunctional III Radiotherapy 25 4.4 
10 63 g.14487 G>A p.R273H Exon 8 Missense Nonfunctional II Multiagent chemotherapy 16 2.3 
11 63 g.14513 C>T p.R282W Exon 8 Missense Nonfunctional IV Multiagent chemotherapy 15 2.0 
12 75 g.14517 G>A p.R283H Exon 8 Missense Functional IV Multiagent chemotherapy 15 1.3 

PFS indicates progression-free survival; OS, overall survival; and NA, not applicable.

*

Genomic numbers refer to reference sequence U94788.

†

Predicted amino acid numbers refer to a translation of NM000546.

‡

Predicted structural and functional characteristics of the mutations were obtained from the mutation validation tool of the IARC TP53 Mutation Database.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal